|Dr. Adam R. Craig||Pres, CEO, Interim Chief Medical Officer & Director||883.58k||N/A||1966|
|Mr. David H. Kirske||Exec. VP, CFO & Sec.||480.75k||N/A||1954|
|Mr. Bruce J. Seeley||Exec. VP & COO||582.25k||N/A||1964|
|Mr. Ed Bell||Sr. Director of Investor Relations||N/A||N/A||N/A|
|Mr. Jim Fong||Sr. VP of US Commercial Operations||N/A||N/A||N/A|
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; University of Vermont; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
CTI BioPharma Corp.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 2; Compensation: 10.